Unit information prior for incorporating real-world evidence into randomized controlled trials

被引:0
作者
Zhang, Hengtao [1 ]
Yin, Guosheng [1 ,2 ]
机构
[1] Univ Hong Kong, Dept Stat & Actuarial Sci, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Stat & Actuarial Sci, Pokfulam Rd, Hong Kong, Peoples R China
关键词
Clinical trials; evidence synthesis; informative prior; observational studies; summary statistics; PROPENSITY-SCORE; METAANALYSIS;
D O I
10.1177/09622802221133555
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Randomized controlled trials (RCTs) have been widely recognized as the gold standard to infer the treatment effect in clinical research. Recently, there has been growing interest in enhancing and complementing the result in an RCT by integrating real-world evidence from observational studies. The unit information prior (UIP) is a newly proposed technique that can effectively borrow information from multiple historical datasets. We extend this generic approach to synthesize the non-randomized evidence into a current RCT. Not only does the UIP only require summary statistics published from observational studies for ease of implementation, but it also has clear interpretations and can alleviate the potential bias in the real-world evidence via weighting schemes. Extensive numerical experiments show that the UIP can improve the statistical efficiency in estimating the treatment effect for various types of outcome variables. The practical potential of our UIP approach is further illustrated with a real trial of hydroxychloroquine for treating COVID-19 patients.
引用
收藏
页码:229 / 241
页数:13
相关论文
共 38 条
  • [1] An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
    Austin, Peter C.
    [J]. MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (03) : 399 - 424
  • [2] No Head-to-Head Trial? Simulate the Missing Arms
    Caro, J. Jaime
    Ishak, K. Jack
    [J]. PHARMACOECONOMICS, 2010, 28 (10) : 957 - 967
  • [3] Hydroxychloroquine for the Prevention of Covid-19-Searching for Evidence
    Cohen, Myron S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) : 585 - 586
  • [4] Combining randomized and nonrandomized evidence in network meta-analysis
    Efthimiou, Orestis
    Mavridis, Dimitris
    Debray, Thomas P. A.
    Samara, Myrto
    Belger, Mark
    Siontis, George C. M.
    Leucht, Stefan
    Salanti, Georgia
    [J]. STATISTICS IN MEDICINE, 2017, 36 (08) : 1210 - 1226
  • [5] Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
    Geleris, Joshua
    Sun, Yifei
    Platt, Jonathan
    Zucker, Jason
    Baldwin, Matthew
    Hripcsak, George
    Labella, Angelena
    Manson, Daniel K.
    Kubin, Christine
    Barr, R. Graham
    Sobieszczyk, Magdalena E.
    Schluger, Neil W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25) : 2411 - 2418
  • [6] Gerlovin H., 2021, AM J EPIDEMIOL
  • [7] A review of the use of propensity score diagnostics in papers published in high-ranking medical journals
    Granger, Emily
    Watkins, Tim
    Sergeant, Jamie C.
    Lunt, Mark
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2020, 20 (01)
  • [8] Greifer N., 2020, WEIGHTIT WEIGHTING C
  • [9] Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
    Guyot, Patricia
    Ades, A. E.
    Ouwens, Mario J. N. M.
    Welton, Nicky J.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2012, 12
  • [10] Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial
    Hernandez-Cardenas, Carmen
    Thirion-Romero, Ireri
    Rodriguez-Llamazares, Sebastian
    Rivera-Martinez, Norma E.
    Meza-Meneses, Patricia
    Remigio-Luna, Arantxa
    Perez-Padilla, Rogelio
    [J]. PLOS ONE, 2021, 16 (09):